Scrip Asia 100 - Taiwanese studies on the up
This article was originally published in Scrip
Executive Summary
The growing number of CROs looking to operate and undertake clinical trials in Taiwan is hardly surprising. The quality of trials is equivalent to those carried out in more established nations in this field, including those of Western Europe, the US and Japan. Furthermore, Taiwan adheres closely to ICH-GCP guidelines, which were introduced by the Department of Health (DoH) in 1997 and revised in 2002. The pitfall for CROs is that, as befits a well-educated population, it appears that patients undergoing clinical trials in Taiwan are not as naive as in other countries in which such studies are more at a development stage.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.